Effect of topical 0.5% timolol on tear flow in patients with primary open-angle glaucoma as assessed by fluorophotometry. 1993

M Göbbels, and T Mönks, and M Spitznas
Universitäts-Augenklinik, Bonn, Germany.

The question as to whether or not topical medication with beta blockers causes a decrease in tear production remains unanswered. Earlier studies using filter-paper strip tests have yielded contradictory results. In the present study, computerized objective fluorophotometry was used to assess the effect of topical medication with 0.5% timolol (b.i.d.; OU) on tear volume and tear production in 24 consecutive patients with bilateral primary open-angle glaucoma. Tear-film fluorophotometry was performed before treatment as well as at 7 days, 14 days, and 4-7 months after the onset of treatment. The results showed that by 7 days after the initiation of timolol treatment, both tear volume (-29%, P < 0.01) and tear secretion (-36%, P < 0.01) had decreased significantly. However, at both 14 days and 4-7 months after the onset of treatment, none of the values differed significantly from those obtained before treatment. Thus, topical antiglaucomatous treatment with 0.5% timolol eye drops leads to a transient decrease in tear production. This effect, however, lasts no longer than 14 days after the beginning of treatment.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009883 Ophthalmic Solutions Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D005902 Glaucoma, Open-Angle Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris. Glaucoma Simplex,Glaucoma, Pigmentary,Glaucoma, Simple,Open-Angle Glaucoma,Chronic Primary Open Angle Glaucoma,Glaucoma, Compensated,Glaucoma, Compensative,Glaucoma, Open Angle,Glaucoma, Primary Open Angle,Glaucoma, Secondary Open Angle,Primary Open Angle Glaucoma,Secondary Open Angle Glaucoma,Compensated Glaucoma,Compensative Glaucoma,Open Angle Glaucoma,Open Angle Glaucomas,Open-Angle Glaucomas,Pigmentary Glaucoma,Simple Glaucoma,Simplex, Glaucoma,Simplices, Glaucoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D013666 Tears The fluid secreted by the lacrimal glands. This fluid moistens the CONJUNCTIVA and CORNEA. Meibomian Lipids,Meibum,Lipid, Meibomian,Meibomian Lipid,Tear
D013999 Timolol A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor. (S)-1-((1,1-Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadazol-3-yl)oxy)-2-propanol,2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)-,Blocadren,L-714,465,MK-950,Optimol,Timacar,Timolol Hemihydrate,Timolol Maleate,Timolol Maleate, (1:1) Salt,Timoptic,Timoptol,L 714,465,L714,465,MK 950,MK950
D015590 Fluorophotometry Measurement of light given off by fluorescein in order to assess the integrity of various ocular barriers. The method is used to investigate the blood-aqueous barrier, blood-retinal barrier, aqueous flow measurements, corneal endothelial permeability, and tear flow dynamics. Ocular Fluorophotometry,Vitreous Fluorophotometry,Fluorophotometry, Ocular,Fluorophotometry, Vitreous

Related Publications

M Göbbels, and T Mönks, and M Spitznas
October 2012, Mymensingh medical journal : MMJ,
M Göbbels, and T Mönks, and M Spitznas
October 2001, American journal of ophthalmology,
M Göbbels, and T Mönks, and M Spitznas
November 1992, Investigative ophthalmology & visual science,
M Göbbels, and T Mönks, and M Spitznas
October 1979, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,
M Göbbels, and T Mönks, and M Spitznas
March 2007, British journal of clinical pharmacology,
M Göbbels, and T Mönks, and M Spitznas
January 1991, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
M Göbbels, and T Mönks, and M Spitznas
January 1984, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
Copied contents to your clipboard!